These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Methods of biochemical analysis in hyperliproproteinemias]. Fruchart JC; Clavey V; Vanhoutte G Pathol Biol (Paris); 1983 Apr; 31(4):235-45. PubMed ID: 6408590 [TBL] [Abstract][Full Text] [Related]
45. Hypolipidemia. Malloy MJ; Kane JP Med Clin North Am; 1982 Mar; 66(2):469-84. PubMed ID: 7040848 [TBL] [Abstract][Full Text] [Related]
46. Lipoproteins and apolipoproteins. Making use of their metabolic properties to individualize therapy. Kottke BA Postgrad Med; 1994 Feb; 95(2):51-3, 57-8, 63-5. PubMed ID: 8309863 [TBL] [Abstract][Full Text] [Related]
47. [Autoimmune chylomicronemia--pathogenesis and pathophysiology]. Matsuzawa Y; Kihara S; Kubo M; Tarui S Nihon Rinsho; 1990 Jun; 48(6):1344-50. PubMed ID: 2200900 [No Abstract] [Full Text] [Related]
48. [Arteriosclerosis. I. Pathogenesis of atheromatous focus]. Szostak WB; Kłosiewicz-latoszek L; Cybulska B Wiad Lek; 1985 Jul; 38(14):1031-7. PubMed ID: 3907148 [No Abstract] [Full Text] [Related]
50. [Genetic studies in familial hyperlipoproteinemia, and therapeutic implications]. de Gennes JL Ann Biol Clin (Paris); 1988; 46(1):1-3. PubMed ID: 3389574 [No Abstract] [Full Text] [Related]
51. Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. LaRosa JC; Chambless LE; Criqui MH; Frantz ID; Glueck CJ; Heiss G; Morrison JA Circulation; 1986 Jan; 73(1 Pt 2):I12-29. PubMed ID: 3940679 [TBL] [Abstract][Full Text] [Related]
52. Pathogenesis, evaluation and therapy of hyperlipidemia. Jordan RM J Ark Med Soc; 1987 Jun; 84(1):59-64. PubMed ID: 2956247 [No Abstract] [Full Text] [Related]
53. [Classification and etiology of hyperlipoproteinemia]. Kita T Nihon Naika Gakkai Zasshi; 1991 Jul; 80(7):1141-7. PubMed ID: 1919230 [No Abstract] [Full Text] [Related]
54. High density lipoprotein and coronary artery disease. Campione KM Occup Health Saf; 1981 May; 50(5):25-30. PubMed ID: 7231836 [No Abstract] [Full Text] [Related]
55. Canadian Consensus Conference on Cholesterol: final report. The Canadian Consensus Conference on the Prevention of Heart and Vascular Disease by Altering Serum Cholesterol and Lipoprotein Risk Factors. CMAJ; 1988; 139(11 Suppl):1-8. PubMed ID: 3069192 [No Abstract] [Full Text] [Related]
57. [Lipoprotein receptors and dyslipoproteinemias]. Orbetsova V Vutr Boles; 1984; 23(3):1-7. PubMed ID: 6087571 [No Abstract] [Full Text] [Related]
58. [The role of hypolipidaemic agents in the fight against atherosclerosis (author's transl)]. Jacotot B Nouv Presse Med; 1980 Oct; 9(40):2951-4. PubMed ID: 7443429 [No Abstract] [Full Text] [Related]
59. [Changes in serum lipid and lipoprotein levels in patients with chronic uremia during hemodialysis treatment]. László A; Csalánosiné Németh M; Joó I; Kiss E; Havass Z; Szenohradszki P Orv Hetil; 1986 May; 127(19):1129-31. PubMed ID: 3714258 [No Abstract] [Full Text] [Related]
60. Hyperlipoproteinaemia in renal failure: pathogenesis and perspectives for intervention. Attman PO Nephrol Dial Transplant; 1993; 8(4):294-5. PubMed ID: 8390000 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]